Searchable abstracts of presentations at key conferences on calcified tissues

ba0005cu1.3 | Management of osteoporosis with focus on osteoporosis in men, pregnancy and patients treated with glucocorticoids | ECTS2016

Vertebroplasty and kyphoplasty; evidence based treatment of painful vertebral fractures?

Peel Nicola

Vertebral fractures (VFX) are the most prevalent fracture associated with osteoporosis and often cause severe pain which can become chronic. VFX are associated with a high risk of further fracture, increased mortality, and reduced quality of life. Vertebroplasty and kyphoplasty are techniques involving the percutaneous injection of bone cement into one or more symptomatic fractured vertebrae. In vertebroplasty, cement is injected directly into the bone, while in kyphoplasty, c...

ba0001pp58 | Bone biomechanics and quality | ECTS2013

Diagnostic discrimination of TBS and spine BMD in glucocorticoid-induced and postmenopausal osteoporosis

Paggiosi Margaret , Peel Nicola , Eastell Richard

Glucocorticoids inhibit osteoblast function and cause an increase in osteoblast and osteocyte apoptosis. Bone remodelling defects occur resulting in an increase in fracture risk that cannot be fully explained by decreases in bone mineral density (BMD). We propose that this may be due to alterations in bone quality. Trabecular bone score (TBS) correlates with 3D bone micro-architectural parameters and can be derived directly from grey-level variations within 2D DXA images.<...

ba0005p403 | Osteoporosis: treatment | ECTS2016

Biochemical monitoring of teriparatide efficacy in a real world setting

Pigott Thomas , Eastell Richard , Peel Nicola

Teriparatide is an anabolic agent given to reduce fracture risk in osteoporosis; it increases BMD and bone turnover. For monitoring treatment efficacy, serum PINP shows the greatest increase and low variability; it has been proposed as a marker of individual treatment response. We aimed to evaluate the utility of PINP to monitor teriparatide treatment in clinical practice.We performed a retrospective evaluation of 91 patients treated with teriparatide si...

ba0003oc6.5 | Osteoporosis treatment and the effects of physical activity | ECTS2014

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal women with rsteoporosis: The TRIO study

Gossiel Fatma , Hoyle Christopher , McCloskey Eugene , Walsh Jennifer , Peel Nicola , Eastell Richard

Bisphosphonates are used to treat bone disease characterised by increased bone resorption by inhibiting the activity of mature osteoclasts, resulting in decreased bone turnover. Bisphosphonates may reduce the population of osteoclast precursor cells (OPCs). Our aims were to investigate the effect of bisphosphonates on i) OPCs and ii) bone turnover in postmenopausal women with osteoporosis compared with healthy premenopausal women. Participants were 62 postmenopausal women (mea...

ba0003pp306 | Osteoporosis: treatment | ECTS2014

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

Gossiel Fatma , Naylor Kim , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Paggiosi Margaret , Eastell Richard

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...

ba0003pp330 | Osteoporosis: treatment | ECTS2014

Determinants of bone turnover marker response to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Naylor Kim , Paggiosi Margaret , Gossiel Fatma , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Eastell Richard

Three oral bisphosphonates ibandronate, alendronate, and risedronate are commonly used for the treatment of osteoporosis but they have not previously been compared in the same study. Our aim was to identify determinants of change in bone turnover markers (BTM) in response to these bisphosphonates in a 2-year randomised parallel group trial. We recruited 171 postmenopausal osteoporotic women (<85 years) who were randomised to receive ibandronate (150 mg monthly), alendronat...

ba0005oc3.4 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

The response of fibroblast growth factor-23 to teriparatide in postmenopausal osteoporosis

Gossiel Fatma , McCloskey Eugene , Walsh Jennifer , Naylor Kim , Peel Nicola , Eastell Richard

FGF-23 is a phosphate regulating hormone and its production may be stimulated by circulating levels of 1,25-dihydroxyvitamin D (1,25-(OH)2D). Teriparatide administration increases levels of 1,25-(OH)2D, however it is unclear whether this mediates changes in FGF-23 levels. The aims were i) to determine the effect of teriparatide treatment on circulating levels of FGF-23 and 1,25-(OH)2D and ii) to describe the time course of effect in postmenopau...